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The pharmacological treatment of obsessive-compulsive
disorder (OCD) and obsessive-compulsive symptoms
(OCS) can be a clinical challenge. The prevalence of
OCD in the general population is 1-2%, but the pre-
valence of OCS is 12% in schizophrenia1 and 16% in
bipolar disorder.2
Antipsychotic agents are used for augmentation in
severe OCD. Conversely, in schizophrenia, clozapine and,
to a lesser extent, olanzapine and risperidone have been
associated with worsening or de novo development of
OCS.2,3
We report the case of a patient with primary OCD who
developed a tardive movement disorder that responded to
clozapine augmentation.
A 35-year-old Venezuelan woman of African descent
consulted the first author for severe obsessions about
her skills as a dentist and for repetitively checking her
procedures in front of her clients. These symptoms had
lasted 2 months. She had previously experienced a severe
episode of OCD at the age of 14, which improved
spontaneously but left mild residual symptoms, such as
compulsory cleaning and ordering. She described a lack
of response to trials of quetiapine, lamotrigine, and tran-
scranial magnetic stimulation. Fluoxetine (20 mg/day),
risperidone (1 mg/day), and clonazepam (1 mg/day) were
started, with an excellent response after 1 week of
treatment.
After 3 months, she returned due to dyskinetic move-
ments of her lips and jaws and focal dystonia of the
tongue, which were diagnosed as tardive dyskinesia and
dystonia by a consulting neurologist. Risperidone was
discontinued; biperiden (8 mg/day) was partially effective
for the abnormal movements for 2 months, at which time
OCS recurred, along with severe anxiety associated with
the abnormal mouth movements, which forced her to stop
working. At that time, she was taking fluoxetine 40 mg/day
and clonazepam 1 mg/day. Biperiden was discontinued
and clozapine augmentation was added at bedtime,
starting at 25 mg and escalating to 50 mg after 10 days.
The OCS, abnormal movements, and anxiety improved
considerably, and she was able to resume work 1 month
after starting clozapine augmentation. The only remaining
OCS after clozapine augmentation was described by the
patient as a ‘‘tormenting thought’’ in the early morning,
which was managed with cognitive psychotherapy and
neurofeedback. Figure 1 shows the course of her Abnor-
mal Involuntary Movement Scale (AIMS) and Yale-Brown
Obsessive-Compulsive Scale (Y-BOCS) scores during
clozapine administration.
This report describes a patient with severe, primary,
non-psychotic OCD who, after starting low-dose risper-
idone to augment fluoxetine, unfortunately developed a
tardive movement disorder (dyskinesia/dystonia). Fluox-
etine is a CYP2D6 and CYP3A4 inhibitor, and inhibits
risperidone metabolism. After stopping risperidone, aug-
mentation of fluoxetine and clonazepam with a low dose
of clozapine (50 mg/day) led to improvement in OCS and
abnormal movements. Fluoxetine is a mild inhibitor of
clozapine metabolism, but in typical patients, this effect is
small (equivalent to multiplying the clozapine dose by 1.3).4
The literature supports the use of clozapine for tardive
dyskinesia.5 While there is a concern about using clozapine
in patients with psychosis and OCS,1,3 this report further
contributes to the literature supporting the use of short-term
Figure 1 Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
and Abnormal Involuntary Movement Scale (AIMS) scores
during clozapine administration.
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clozapine augmentation for cases of complicated primary
OCD.
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